Switching TKIs During CML Therapy is Frequent, Mostly Driven by Intolerance, and Does Not Affect Survival: a Prospective Quebec Registry Study

Overview

Journal Blood Cancer J

Date 2025 Mar 12

PMID 40069191

Authors

Lambert Busque

Marc-Etienne Beaudet

Michael Harnois

Hanane Moussa

Natasha Szuber

Luigina Mollica

Robert Delage

Harold Olney

Pierre Laneuville

Ghislain Cournoyer

Ines Chamakhi

Marc Lalancette

Danielle Talbot

Vincent Ethier

Pierre Desjardins

Sarit Assouline

Affiliations

Soon will be listed here.

References

Rea D, Mauro M, Boquimpani C, Minami Y, Lomaia E, Voloshin S . A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs. Blood. 2021; 138(21):2031-2041. PMC: 9728405. DOI: 10.1182/blood.2020009984. View

Held N, Atallah E . Real-world Management of CML: Outcomes and Treatment Patterns. Curr Hematol Malig Rep. 2023; 18(5):167-175. DOI: 10.1007/s11899-023-00703-w. View

Hochhaus A, Wang J, Kim D, Kim D, Mayer J, Goh Y . Asciminib in Newly Diagnosed Chronic Myeloid Leukemia. N Engl J Med. 2024; 391(10):885-898. DOI: 10.1056/NEJMoa2400858. View

Cortes J, Kim D, Kantarjian H, Brummendorf T, Dyagil I, Griskevicius L . Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012; 30(28):3486-92. PMC: 4979199. DOI: 10.1200/JCO.2011.38.7522. View

Jabbour E, Sasaki K, Haddad F, Issa G, Skinner J, Dellasala S . Low-dose dasatinib 50 mg/day versus standard-dose dasatinib 100 mg/day as frontline therapy in chronic myeloid leukemia in chronic phase: A propensity score analysis. Am J Hematol. 2022; 97(11):1413-1418. PMC: 11837974. DOI: 10.1002/ajh.26689. View

Lipton J, Brummendorf T, Gambacorti-Passerini C, Garcia-Gutierrez V, Deininger M, Cortes J . Long-term safety review of tyrosine kinase inhibitors in chronic myeloid leukemia - What to look for when treatment-free remission is not an option. Blood Rev. 2022; 56:100968. DOI: 10.1016/j.blre.2022.100968. View

Kantarjian H, Shah N, Cortes J, Baccarani M, Agarwal M, Undurraga M . Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION). Blood. 2011; 119(5):1123-9. PMC: 4916556. DOI: 10.1182/blood-2011-08-376087. View

Atallah E, Mauro M, Hochhaus A, Boquimpani C, Minami Y, Maheshwari V . Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors. J Cancer Res Clin Oncol. 2023; 149(9):6247-6262. PMC: 10356870. DOI: 10.1007/s00432-022-04562-5. View

Saglio G, Kim D, Issaragrisil S, le Coutre P, Etienne G, Lobo C . Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362(24):2251-9. DOI: 10.1056/NEJMoa0912614. View

10.

Rousselot P, Mollica L, Guilhot J, Guerci A, Nicolini F, Etienne G . Dasatinib dose optimisation based on therapeutic drug monitoring reduces pleural effusion rates in chronic myeloid leukaemia patients. Br J Haematol. 2021; 194(2):393-402. DOI: 10.1111/bjh.17654. View

11.

Hochhaus A, Rea D, Boquimpani C, Minami Y, Cortes J, Hughes T . Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL. Leukemia. 2023; 37(3):617-626. PMC: 9991909. DOI: 10.1038/s41375-023-01829-9. View

12.

La Rosee P, Martiat P, Leitner A, Klag T, Muller M, Erben P . Improved tolerability by a modified intermittent treatment schedule of dasatinib for patients with chronic myeloid leukemia resistant or intolerant to imatinib. Ann Hematol. 2013; 92(10):1345-50. DOI: 10.1007/s00277-013-1769-2. View

13.

Atallah E, Sweet K . Treatment-Free Remission: the New Goal in CML Therapy. Curr Hematol Malig Rep. 2021; 16(5):433-439. PMC: 8495665. DOI: 10.1007/s11899-021-00653-1. View

14.

Bower H, Bjorkholm M, Dickman P, Hoglund M, Lambert P, Andersson T . Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population. J Clin Oncol. 2016; 34(24):2851-7. DOI: 10.1200/JCO.2015.66.2866. View